Overview
Sweden life science supplier's Q1 net sales fell 2% and missed analyst expectations
EBITA margin held at 12.5% despite negative currency impact
Company completed two acquisitions in UK and Austria to support growth
Result Drivers
DIVESTMENTS AND ACQUISITIONS - Organic growth was 3% and acquired growth 2%, but overall sales fell due to divested operations and negative currency effects
CURRENCY IMPACT - Exchange rate effects reduced both sales and EBITA by 4%
Company press release: ID:nMFNbhMZyc
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
Miss
SEK 2.65 bln
SEK 2.74 bln (4 Analysts)
Q1 EPS
SEK 1.04
Q1 Net Income
SEK 128 mln
Q1 EBITA
SEK 332 mln
Q1 EBITA Margin
12.50%
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AddLife AB is SEK190.00, about 25.1% above its April 27 closing price of SEK151.90
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 27 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
